Granulomatosis with polyangiitis
Drug research and approvals for granulomatosis with polyangiitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 24 studies of granulomatosis with polyangiitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 4 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 24
- Trials authorized in Canada: 4
- FDA orphan approvals: 4
- EU medicines: 0
- Benralizumab Effectiveness in EGPANCT07815886 · Not reported · European EGPA Study Group · starts Feb 11, 2026
- Ocular Manifestations of Granulomatosis With Polyangiitis.NCT07664709 · Not reported · Military Institute od Medicine National Research Institute · starts Mar 1, 2024
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit…NCT07444567 · Phase 3 · AstraZeneca · starts Jul 24, 2026
- The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With…NCT07275190 · Not applicable · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Jun 1, 2025
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With PolyangiitisNCT07176546 · Phase 2 / Phase 3 · Robert Spiera, MD · starts May 22, 2026
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · Phase 2 · NYU Langone Health · starts Dec 12, 2025
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesNCT07087912 · Phase 4 · University of Sao Paulo General Hospital · starts Mar 16, 2026
- Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)NCT06983821 · Phase 3 · Ottawa Hospital Research Institute · starts Nov 10, 2025
- Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With PolyangiitisNCT06940661 · Phase 2 · Assistance Publique - Hôpitaux de Paris · starts Dec 19, 2025
Approved 2
Phase 3 9
- AzathioprineAmidophosphoribosyltransferase inhibitor
- CyclophosphamideDNA inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- PrednisoneGlucocorticoid receptor agonist
- MethotrexateDihydrofolate reductase inhibitor
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- MepolizumabInterleukin-5 inhibitor
- Gusperimus
- DepemokimabInterleukin-5 inhibitor
Phase 2 6
- EtanerceptTNF-alpha inhibitor
- VilobelimabComplement C5 inhibitor
- InfliximabTNF-alpha inhibitor
- DaclizumabInterleukin-2 receptor inhibitor
- BlisibimodTumor necrosis factor ligand superfamily member 13B inhibitor
- Prednylidene
Phase 1 or earlier 3
- SulfamethoxazoleBacterial dihydropteroate synthase inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- Interleukin-10
How its trials ended
103 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 22 whose ending is known, 41% met their primary endpoint, 14% missed it and 45% stopped early.
- Completed, result not reported4241%
- Ongoing2524%
- Status unknown1414%
- Met its primary endpoint99%
- Stopped: other or unclear44%
- Missed its primary endpoint33%
- Stopped: enrollment or feasibility33%
- Stopped: funding22%
- Stopped: sponsor or business decision11%
| Mar 27, 2025 | A phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with…YTB323 (rapcabtagene autoleucel) | Novartis Pharmaceuticals | Pending |
| Feb 13, 2025 | Safe effective therapy with low-dose glucocorticoid in anca-associated vasculitis (safe-low) trialCyclophosphamide / Prednisone | Ottawa Hospital Research Institute | Ongoing |
| Apr 24, 2024 | A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active anca-associated vasculitisIptacopan (LNP023) | Novartis Pharmaceuticals | Closed |
| Sep 13, 2023 | A phase 2, double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of NS-229 in the treatment of eosinophilic granulomatosis…NS-229 | NS Pharma Inc | Ongoing |
| Sep 17, 2024 | FasenraTreatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) | AstraZeneca Pharmaceuticals LP | Approved |
| Oct 7, 2021 | TavneosAs an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis… | ChemoCentryx, Inc. | Approved |
| Sep 27, 2019 | RituxanRITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with… | Genentech, Inc. | Approved |
| Jun 6, 2019 | NucalaNUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis… | GlaxoSmithKline LLC | Approved |
| Apr 14, 2025 | Small molecule, selective Janus kinase (JAK) 1 inhibitorTreatment of eosinophilic granulomatosis with polyangiitis | NS Pharma, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA